Why the study?
Does methoxy-verapamil reduce infarct size depending on the extent of the area at risk in dogs with coronary artery occlusion?
Does methoxy-verapamil reduce infarct size depending on the extent of the area at risk in dogs with coronary artery occlusion?
The effectiveness of methoxy-verapamil in reducing myocardial infarct size is inversely related to the size of the initial area at risk.
Methoxy-verapamil may limit infarct size in canine models, especially with small areas at risk; leaves open translation to human acute coronary occlusion.
The goal of this study was to examine whether the effectiveness of a drug in protecting ischemic myocardium depends on the size of the hypoperfused zone (the area at risk) measured immediately after coronary artery occlusion (CAO).Methoxy-verapamil (D600), a potent calcium antagonist, was used to test this hypothesis.In 68 dogs, 1 minute after CAO, 8 mCi of technetium-99m-labeled albumin microspheres were injected into the left atrium for later assessment of the hypoperfused zone by autoradiog- raphy.Eighteen dogs were treated with D600 (0.8 mg/kg as a bolus 15 minutes after CAO and 0.2 mg/kg/ hour as a continuous infusion for 6 hours).After 6 hours, the hearts were excised and the left ventricles cut into 3-mm-thick slices and stained with triphenyltetrazolium chloride.The extent of myocardial damage was measured by planimetry of the unstained areas.Thereafter, the same slices were autoradiographed and the extent of the hypoperfused zones measured by planimetry of the "cold spots."Both the treated and control dogs were classified according to the amount of the left ventricle that was hypoperfused: small (< 25%), medium (25-30%), and large (> 30%).In control dogs with small, medium and large hypoperfused zones, the percentages of the hypoperfused zone that evolved to infarction were 95.9 + 3.5% (mean ± SEM), 90.8 3.5%, and 93.1 ± 2.6%, respectively; in the D600-treated dogs, 31.9 ± 8.3%, 53.8 ± 3.0%, and 61.3 9.2%, respectively.Thus, the dogs with the smallest areas at risk had the most extensive reduction in damage (67%); the effectiveness of treatment was intermediate in those with medium areas at risk (41%) and treatment had the least effect in those with the largest area at risk (34%).Thus, the size of the area at risk, determined in vivo immediately after CAO, is an important factor in determining the effectiveness of a drug in reducing myocardial damage.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: